Trials / Recruiting
RecruitingNCT05776342
Prognostic and Predictive Markers of Treatment Response in Patients With PAC.
Prognostic and Predictive Markers of Treatment Response in Patients With Pancreatic Adenocarcinoma
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,050 (estimated)
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy,...) in patients with pancreatic adenocarcinoma. The effectiveness and tolerance of these treatments in current practice is also evaluated.
Detailed description
The modest efficacy of current therapies for pancreatic cancer calls for the development of prognostic factors to guide patient selection and clinical decision-making based on tumor aggressiveness and risk of death. The aim of this study is to identify prognostic and predictive factors of response to treatments administered in pancreatic adenocarcinoma, based on a multicenter cohort established on a population derived from current clinical practice. By accurately stratifying patients according to their estimated survival, prognostic tools could aid therapeutic decisions and optimize patient selection in future clinical trials.
Conditions
Timeline
- Start date
- 2003-01-01
- Primary completion
- 2030-12-31
- Completion
- 2031-12-31
- First posted
- 2023-03-20
- Last updated
- 2025-03-25
Locations
15 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05776342. Inclusion in this directory is not an endorsement.